Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

Recruiting now

Conditions studied: Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Precancerous Condition

In brief

RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer.

Key facts

Study ID

NCT00900419

Run by

University of Colorado, Denver

People needed

700

Starts

2001-05-03

Expected to finish

2027-09-30

Last updated by the study team

2025-09-22

Who can join

Age: 21 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of extensive and severe dysplasia of the respiratory epithelium
• Those without dysplasia of the respiratory epithelium
• Recruited from the SPORE Tissue Procurement Screening Project or by private or academic physicians (for patients with moderate or severe dysplasia)
• Survived 1 or more aerodigestive system carcinoma for ≥ 1 year
• Completely resected stage I non-small cell cancer
• Undergoing any of the following procedures:
• Routine panendoscopy for patients with head and neck cancer
• Resection of a bronchogenic carcinoma
• Bronchoscopy for diagnosis or staging of suspected lung cancer
• Subsequent bronchoscopy for surveillance or monitoring of response to endobronchial treatment in patients with prior high-grade dysplasia or worse
• No asthma
• No lung disease
• No respiratory illness within the past 2 weeks Patients suspected of or at risk for neoplastic lung disease who are undergoing a bronchoscopy in which differential diagnostic considerations may include multiple other etiologies such as infection and other processes.
• Patients without dysplasia will be: patients undergoing clinically indicated bronchoscopy for conditions other than suspected lung cancer.
• PATIENT CHARACTERISTICS:
• No clinically apparent bleeding diathesis
• No known bleeding disorder
• No anginal
• No clinically active coronary artery disease
• No multifocal premature ventricular contractions
• No poorly controlled congestive heart failure
• No myocardial infarction within the past 6 weeks
• No cardiac dysrhythmia that is potentially life threatening
• Well-controlled atrial fibrillation or rare (< 2/min) premature ventricular contractions allowed
• No ventricular tachycardia or supraventricular tachycardia with a rapid ventricular response

Where it is running

• University of Colorado Cancer Center at UC Health Sciences Center — Aurora, Colorado, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.